Published in Lab Business Week, February 12th, 2006
"To improve bystander cell killing with HSV-TK/GCV, we have utilized dFdCyd to reduce endogenous dGTP, which competes with GCVTP for incorporation into DNA," wrote P.D. Boucher and colleagues, University of Michigan.
The authors wrote, "In vitro, dFdCyd reduced cellular dGTP levels and produced a fourfold increase in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.